|
TIGRESS - Thrombophilia and Intrauterine Growth Restriction Study
Principal Investigator: Dr. Marc Rodger
Co-Investigators: Dr. Mark Walker, Dr. Shi Wu Wen, Dr. Philip Wells, Dr. Rama Nair
Funding Agency: Canadian Institutes of Health Research
Background and Significance:
Thrombophilias are common, inherited and acquired, predispositions to develop venous thromboembolism. The most common genetic thrombophilias are Factor V Leiden (FVL) and prothrombin gene variant (PGV), with a combined population prevalence of 5.6% - 10%. Intrauterine growth restriction (IUGR) is a common pregnancy complication (by definition 10% of newborns are affected) and represents a large disease burden for infants, their families, and society.
Thrombophilia may predispose pregnant women to delivering an IUGR infant by causing thrombosis in the placental circulation and subsequent placental insufficiency. The literature examining the association between thrombophilia and IUGR remains inconclusive. Given that thrombophilia and IUGR are common, if a significant association is demonstrated between FVL/PGV and IUGR, then a large proportion of the population-attributable risk of IUGR may be identified. If so, then there may be justification for routine thrombophilia screening of all pregnant women and further efforts to develop preventive or therapeutic measures in thrombophilic pregnancies (e.g. antithrombotic prophylaxis).
Objective:
To determine the association between thrombophilia [specifically Factor V Leiden (FVL) or prothrombin gene variant (PGV)] and intrauterine growth restriction (IUGR).
“Practice changing knowledge generation, developing tomorrow's leaders and delivering quality cost effective care.”
| |
